BRG announced today that Rich Rieger has joined the firm's Health Analytics practice, where he will advise biopharmaceutical and MedTech companies on driving growth, performance improvement and ...

The stock market has been volatile to kick off 2025, with many top tech stocks well off their highs as some investors ...

Miami International Holdings, Inc. (MIH), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today announced it will migrate Minneapolis ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...